Citations

Citations to this article as recorded by  

• A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer
  Ritesh R. Kotecha, Sahil D. Doshi, Andrea Knezevic, Joshua Chaim, Yingbei Chen, Rachel Jacobi, Mark Zucker, Ed Reznik, Deaglan McHugh, Neil J. Shah, Emily Feld, David H. Aggen, William Rafelson, Han Xiao, Maria I. Carlo, Darren R. Feldman, Chung-Han Lee,
  European Urology Oncology.2024; 7(4): 804.     CrossRef
• Hereditary Renal Cancer Syndromes
  Grigory A. Yanus, Ekaterina Sh. Kuligina, Evgeny N. Imyanitov
  Medical Sciences.2024; 12(1): 12.     CrossRef
• Fumarate Hydratase-Deficient Renal Cell Carcinoma—A Clinicopathological Study of a Series of 11 Cases
  Aswathy A. Menon, Swapnil Rane, Uma Sakhadeo, Gagan Prakash, Amit Joshi, Mahendra Pal, Amandeep Arora, Nilesh Sable, Aparna Katdare, Palak Popat, Priyamvada Maitre, Archi Agarwal, Vedang Murthy, Sangeetha B. Desai, Santosh Menon
  Indian Journal of Medical and Paediatric Oncology.2024;[Epub]     CrossRef
• Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
  Junru Chen, Xu Hu, Junjie Zhao, Xiaoxue Yin, Linmao Zheng, Jingjing Guo, Jianhui Chen, Yongquan Wang, Xinan Sheng, Haiying Dong, Xiaodong Liu, Xingming Zhang, Jiayu Liang, Haolin Liu, Jin Yao, Jiyan Liu, Yali Shen, Zhibin Chen, Zhengyu He, Yaodong Wang, N
  Clinical Cancer Research.2024; 30(11): 2571.     CrossRef
• Comparison of Primary and Metastatic Fumarate Hydratase-Deficient Renal Cell Carcinomas Documents Morphologic Divergence and Potential Diagnostic Pitfall With Peritoneal Mesothelioma
  Anna Caliò, Stefano Marletta, Lavinia Stefanizzi, Lisa Marcolini, Matteo Rotellini, Gabriella Serio, Elena Bariani, Caterina Vicentini, Serena Pedron, Filippo M. Martelli, Pietro Antonini, Matteo Brunelli, Guido Martignoni
  Modern Pathology.2024; 37(9): 100561.     CrossRef
• Bevacizumab-Based Therapies in Malignant Tumors—Real-World Data on Effectiveness, Safety, and Cost
  Elena Chitoran, Vlad Rotaru, Sinziana-Octavia Ionescu, Aisa Gelal, Cristina-Mirela Capsa, Roxana-Elena Bohiltea, Madalina-Nicoleta Mitroiu, Dragos Serban, Giuseppe Gullo, Daniela-Cristina Stefan, Laurentiu Simion
  Cancers.2024; 16(14): 2590.     CrossRef
• Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
  Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
  Cancer Research and Treatment.2024; 56(3): 721.     CrossRef
• Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
  Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
  Journal of Pathology and Translational Medicine.2024; 58(4): 147.     CrossRef
• Complete response to fifth-line anti-PD-1 rechallenge in fumarate hydratase-mutated papillary renal cell carcinoma
  Isabella Portugal, Maria A. Clavijo-Salomon
  npj Precision Oncology.2024;[Epub]     CrossRef
• Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
  Yunze Xu, Wen Kong, Ming Cao, Jieying Wang, Zaoyu Wang, Liang Zheng, Xiaoyu Wu, Rongrong Cheng, Wei He, Bo Yang, Baijun Dong, Jiahua Pan, Yonghui Chen, Jiwei Huang, Chen Jiang, Wei Zhai, Fangzhou Li, Ruohua Chen, Xiang Zhou, Guangyu Wu, Xiaochuan Geng, Ji
  European Urology.2023; 83(2): 163.     CrossRef
• Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature
  Alexius John, Lavinia Spain, Anis A. Hamid
  Current Oncology.2023; 30(1): 923.     CrossRef
• CLC-Pred 2.0: A Freely Available Web Application for In Silico Prediction of Human Cell Line Cytotoxicity and Molecular Mechanisms of Action for Druglike Compounds
  Alexey A. Lagunin, Anastasia V. Rudik, Pavel V. Pogodin, Polina I. Savosina, Olga A. Tarasova, Alexander V. Dmitriev, Sergey M. Ivanov, Nadezhda Y. Biziukova, Dmitry S. Druzhilovskiy, Dmitry A. Filimonov, Vladimir V. Poroikov
  International Journal of Molecular Sciences.2023; 24(2): 1689.     CrossRef
• Fumarate Hydratase-deficient Renal Cell Carcinoma
  Yi-Hsuan Huang, Nan-Haw Chow, Yu-Ting Yu, Wen-Pin Su
  Journal of Cancer Research and Practice.2023; 10(1): 28.     CrossRef
• Diseases of Hereditary Renal Cell Cancers
  Othon Iliopoulos
  Urologic Clinics of North America.2023; 50(2): 205.     CrossRef
• Hereditary Leiomyomatosis and Renal Cell Cancer: A Case Report of Pilar Leiomyomatosis with History of Kidney Cancer and Review of the Literature
  Jee-Woo Kim, Jung-Won Shin, Anna Cho, Chang-Hun Huh
  Annals of Dermatology.2023;[Epub]     CrossRef
• Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas
  Xinfeng Hu, Congzhu Tan, Guodong Zhu
  Current Issues in Molecular Biology.2023; 45(6): 4763.     CrossRef
• Hereditary predisposition to kidney cancer: cancer syndromes, multisystemic disorders, and nephropathies
  G. A. Yanus, A. G. Iyevleva, E. N. Suspitsin, A. V. Tumakova, E. V. Belogubova, S. N. Aleksakhina, A. V. Togo, E. N. Imyanitov
  Sechenov Medical Journal.2023; 14(2): 5.     CrossRef
• Hereditary leiomyomatosis and renal cell cancer associated with metastatic rectal cancer
  Parikshit Padhi, Naga Praneeth Raja
  Current Problems in Cancer: Case Reports.2023; 11: 100257.     CrossRef
• Unmasking the enigma: A case of Fumarate Hydratase-deficient renal cell carcinoma
  Mirza Rameez Samar, Wajiha Khan, Yasmin Abdul Rashid, Azmina Tajuddin Vali Mohammad
  International Journal of Surgery Case Reports.2023; 113: 109054.     CrossRef
• Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists’ ever-expanding differential diagnosis for a heterogeneous group of entities
  Alexander S. Taylor, Stephanie L. Skala
  Urologic Oncology: Seminars and Original Investigations.2022; 40(12): 499.     CrossRef
• Low-Grade Fumarate Hydratase-Deficient Renal Cell Carcinoma in a 30-Year-Old Female
  Nicolas Wyvekens, William J. Anderson, Young X. Kim, Mark Carter, Michelle S. Hirsch
  International Journal of Surgical Pathology.2022; 30(2): 184.     CrossRef
• Response to the Letter to the Editor Entitled “Do We Have Sufficient Evidence to Define Prognosis for ‘Low-grade’ Fumarate Hydratase-deficient Renal Cell Carcinoma?”
  Steven C. Smith, Ameer Hamza, Deepika Sirohi, Mahul B. Amin
  Advances in Anatomic Pathology.2022; 29(3): 181.     CrossRef
• Hereditary Renal Cell Carcinoma
  Scott J. Dawsey, Shilpa Gupta
  Kidney Cancer.2022; 6(2): 83.     CrossRef
• A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma
  Zizhen Feng, Brendan D. Curti, David I. Quinn, John M. Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M. Beer, Christopher W. Ryan
  Clinical Genitourinary Cancer.2022; 20(5): 415.     CrossRef
• Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma
  Andrea Katharina Lindner, Gennadi Tulchiner, Andreas Seeber, Peter J. Siska, Martin Thurnher, Renate Pichler
  Frontiers in Oncology.2022;[Epub]     CrossRef
• MR Spectroscopy for Detecting Fumarate Hydratase Deficiency in Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome
  Guangyu Wu, Guiqin Liu, Jianfeng Wang, Shihang Pan, Yuansheng Luo, Yunze Xu, Wen Kong, Peng Sun, Jianrong Xu, Wei Xue, Jin Zhang
  Radiology.2022; 305(3): 631.     CrossRef
• Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report
  Yasuhiro Iribe, Mitsuko Furuya, Yousuke Shibata, Masato Yasui, Makoto Funahashi, Junichi Ota, Hiromichi Iwashita, Yoji Nagashima, Hisashi Hasumi, Narihiko Hayashi, Kazuhide Makiyama, Keiichi Kondo, Reiko Tanaka, Masahiro Yao, Noboru Nakaigawa
  Familial Cancer.2021; 20(1): 75.     CrossRef
• Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients
  Ja Young Seo, Jeong-Yeal Ahn, Bhumsuk Keam, Miso Kim, Shinkyo Yoon, Jae Lyun Lee, Kwonoh Park, Inkeun Park
  Annals of Laboratory Medicine.2021; 41(2): 207.     CrossRef
• Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma
  Guangxi Sun, Xingming Zhang, Jiayu Liang, Xiuyi Pan, Sha Zhu, Zhenhua Liu, Cameron M. Armstrong, Jianhui Chen, Wei Lin, Banghua Liao, Tianhai Lin, Rui Huang, Mengni Zhang, Linmao Zheng, Xiaoxue Yin, Ling Nie, Pengfei Shen, Jinge Zhao, Haoran Zhang, Jindon
  Clinical Cancer Research.2021; 27(6): 1734.     CrossRef
• Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation
  Marianne Spengler, Megan Wheelden, Heath B. Mackley, Joseph J. Drabick
  JCO Precision Oncology.2021; (5): 664.     CrossRef
• Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
  Andrew J. Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K. Bathala, Amishi Y. Shah, Eric Jonasch, Vince D. Cataldo, Giannicola Genovese, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Pavlos Msaouel
  Cancers.2021; 13(9): 2170.     CrossRef
• Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma
  Lucia Carril-Ajuria, Emeline Colomba, Luigi Cerbone, Carmen Romero-Ferreiro, Laurence Crouzet, Brigitte Laguerre, Constance Thibault, Cécile Vicier, Guillermo de Velasco, Aude Fléchon, Carolina Saldana, Patrick R. Benusiglio, Brigitte Bressac-de Pailleret
  European Journal of Cancer.2021; 151: 106.     CrossRef
• Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment
  Congwang Zhang, Lijun Li, Yipeng Zhang, Changchun Zeng
  Frontiers in Oncology.2021;[Epub]     CrossRef
• Hereditary leiomyomatosis and renal cell cancer presenting as urothelial carcinoma
  Samuel B Reynolds, Rishi Charate, Quang L Nguyen, Padmini Moffett
  Journal of Onco-Nephrology.2021; 5(3): 178.     CrossRef
• Das FH-defiziente Nierenzellkarzinom erweitert das Spektrum der papillären Tumoren in der Niere
  N. Rupp, H. Moch
  Der Pathologe.2021; 42(6): 560.     CrossRef
• To treat or not to treat: a clinical series of retinal arterial macroaneurysms
  Wan-Hua Cho, Wei-Yu Chiang, Chih-Hsin Chen, Hsi-Kung Kuo
  Medicine.2020; 99(5): e19077.     CrossRef
• Bevacizumab/erlotinib
  
  Reactions Weekly.2020; 1798(1): 61.     CrossRef
• On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy
  Janice P. Dutcher, Ronan Flippot, Jaleh Fallah, Bernard Escudier
  American Society of Clinical Oncology Educational Book.2020; (40): 418.     CrossRef
• Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach
  Nicolas Wyvekens, Nadejda Valtcheva, Axel Mischo, Birgit Helmchen, Thomas Hermanns, Matthias Choschzick, Andreas M. Hötker, Anita Rauch, Beda Mühleisen, Dilara Akhoundova, Achim Weber, Holger Moch, Niels J. Rupp
  Genes, Chromosomes and Cancer.2020; 59(11): 611.     CrossRef
• Fumarate hydratase as a therapeutic target in renal cancer
  Priyanka Kancherla, Michael Daneshvar, Rebecca A. Sager, Mehdi Mollapour, Gennady Bratslavsky
  Expert Opinion on Therapeutic Targets.2020; 24(9): 923.     CrossRef
• Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma
  Shuheng Bai, YinYing Wu, Yanli Yan, Shuai Shao, Jiangzhou Zhang, Jiaxin Liu, Beina Hui, Rui Liu, Hailin Ma, Xiaozhi Zhang, Juan Ren
  Scientific Reports.2020;[Epub]     CrossRef